Defining prognosis for women with breast cancer and CNS metastases by HER2 status

Dawood, Shaheenah; Broglio, Kristine; Esteva, Francisco J.; Ibrahim, Nuhad K.; Kau, Shu Wan; Islam, Rabiul; Aldape, Kenneth; Yu, Tse-Kuan; Hortobágyi, Gabriel N.; Gonzalez-Angulo, Ana-Maria

doi:10.1093/annonc/mdn036

Cited by 181 publications

(160 citation statements)

References 16 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…Our study were in accordance with many studies ( Dawood et al, 2008;Moradi Marjaneh et al, 2008) that revealed PR and HER-2 do not have effect on survival, but in some studies HER-2 was a prognostic factors (Khodabakhshi et al, 2011). Protein P53 was not prognostic factor for survival.…”

Section: Discussionsupporting

confidence: 93%

Predictive Factors of Survival Time of Breast Cancer in Kurdistan Province of Iran between 2006-2014: A Cox Regression Approach

Karimi

Delpisheh²,

Sayehmiri³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Breast cancer is a major cause of morbidity and cancer related mortality among women. The prevalence of breast cancer was reported as increasing in most of the Asian countries (Aini abdullah et al., 2013;Najafi et al., 2013). Iran is also sharing the same experience. The etiology of breast cancer is largely unknown; therefore there is no established primary prevention strategy. So, the main strategy is the establishment of screening protocols and early detection programs, which at least theoretically can improve the survival rates. Despite the increasing incidence, the survival rates of breast cancer patients in many developed countries were substantially improved. According to national cancer registry project report, breast cancer is the most common cancer and also the most common cause of cancer-related deaths of female population in Iran (Mohagheghi et al., 2009).According to international agency for research on

show abstract

Section: Discussionsupporting

confidence: 93%

Predictive Factors of Survival Time of Breast Cancer in Kurdistan Province of Iran between 2006-2014: A Cox Regression Approach

Karimi

Delpisheh²,

Sayehmiri³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Results from our study further illustrate that the incidence of CNS metastasis in patients with HER2-positive disease is significantly higher in patients treated with trastuzumab than in those not treated with trastuzumab (37.8 vs 25.0%, respectively, P ¼ 0.028). This finding can be explained by both the known aggressive nature and by the increased predilection to CNS metastases of HER2-positive tumours (Dawood et al, 2008). In addition, adding trastuzumab did not affect the development of BMs in HER2-overexpressing breast cancer, which is associated with the poor penetration of trastuzumab across the blood-brain barrier (BBB) and poor activity in BMs.…”

Section: Discussionmentioning

confidence: 97%

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

et al. 2009

Br J Cancer

164

107

View full text Add to dashboard Cite

In patients with human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer, treatment with trastuzumab has been shown to markedly improve the outcome. We investigated the role of trastuzumab on brain metastasis (BM) in HER2-positive breast cancer patients. From 1999 to 2006, 251 patients were treated with palliative chemotherapy for HER2-positive metastatic breast cancer at Samsung Medical Center. The medical records of these patients were analysed to study the effects of trastuzumab on BM prevalence and outcomes. Patients were grouped according to trastuzumab therapy: pre-T (no trastuzumab therapy) vs post-T (trastuzumab therapy). The development of BM between the two treatment groups was significantly different (37.8% for post-T vs 25.0% for pre-T, P ¼ 0.028). Patients who had received trastuzumab had longer times to BM compared with patients who were not treated with trastuzumab (median 15 months for post-T group vs 10 months for pre-T group, P ¼ 0.035). Time to death (TTD) from BM was significantly longer in the post-T group than in the pre-T group (median 14.9 vs 4.0 months, P ¼ 0.0005). Extracranial disease control at the time of BM, 12 months or more of progression-free survival of extracranial disease and treatment with lapatinib were independent prognostic factors for TTD from BM.

show abstract

“…Interestingly, despite ineffective delivery of trastuzumab imposed by the blood-brain barrier, some studies suggested that prolonged survival may also include patients who developed brain relapse while on therapy with this agent [14,24,[34][35][36][37][38][39]. For example, in the study of Lower et al [14] the mean survival in patients who developed brain relapse during trastuzumab therapy was 1,400 days, compared to 639 days in patients with brain relapse who were not applied this agent.…”

Section: Discussionmentioning

confidence: 99%

Risk factors for brain relapse in HER2-positive metastatic breast cancer patients

Duchnowska

Dziadziuszko

Czartoryska-Arłukowicz³

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

Cited by 181 publications

References 16 publications

Predictive Factors of Survival Time of Breast Cancer in Kurdistan Province of Iran between 2006-2014: A Cox Regression Approach

Predictive Factors of Survival Time of Breast Cancer in Kurdistan Province of Iran between 2006-2014: A Cox Regression Approach

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

Risk factors for brain relapse in HER2-positive metastatic breast cancer patients

Contact Info

Product

Resources

About